Poster Presentations

Topic 1 | Microenvironment and metabolism

P1.1 | LL-37 inhibits pancreatic cancer development through inhibition of autophagy and reprogramming of the tumor microenvironment
Joshua Ko, Kowloon Tong, Hong Kong

P1.2 | Tissue Slice Culture Platform: A Slice of Reality in Drug Development
Fabien Garcon, Cambridge, United Kingdom

P1.3 | Omental fat in ovarian cancer induces lymphangiogenesis – The role of an adipose-rich microenvironment in tumor progression and metastatic dissemination.
Victor Starrach, Heidelberg, Germany

P1.4 | Reprogramming of M2-like macrophages to M1-like phenotype by tumor-antigen specific CD4+ T cells
Stefan Eichmüller, Heidelberg, Germany

P1.5 | Myeloid cells mediates the accelerated growth of tumor in high-fat diet-fed mice
Thi TRAN, Paris, France

P1.6 | The panta rhei of breast cancer: gene expression timeline analysis during progression of microinvasive breast cancer microenvironment
Francesca Lessi, San Giuliano Terme, Italy

P1.7 | Immunogenic effects of FOLFOXIRI plus Bevacizumab therapy in colorectal peritoneal carcinomatosis
Monika Sachet, Vienna, Austria

P1.8 | Differences in macrophage colonization of the colorectal cancer and normal mucosa
Natalie Walterskirchen, Vienna, Austria

P1.9 | Comparing the immune cell infiltration of colorectal cancer with distant normal mucosa uncovers a prognostically relevant immune cell profile
Rudolf Oehler, Vienna, Austria

P1.10 | Probing the interaction of macrophages in the pancreatic cancer microenvironment using 3D engineered rollable tumour (TRACER)
Ileana Co, Toronto, Canada

P1.11 | Abstract withdrawn

P1.12 | Cholesterol induces CD8+ T-cell exhaustion in the tumor microenvironment
Qing Yi, Houston, United States

P1.13 | Establishing of a primary cancer microtissue model to investigate immune cell infiltration
Stefan Koeck, Innsbruck, Austria

P1.14 | The nonessential amino acid proline enhances migration and proliferation of human melanoma cells
Konstantin Mayr, Vienna, Austria

P1.15 | Glycosylation of the cytokine co-receptor gp130 reveals a rapid protein turnover, which gives raise to biased signalling in human melanoma cells from different disease stages
Katharina Svoboda, Vienna, Austria

P1.16 | Lipid-storing, tumor-associated macrophages orchestrate a tumor-excluded immune landscape in omentum metastases of epithelial ovarian cancer.
Meggy Suarez-Carmona, Heidelberg, Germany

P1.17 | Clearance of apoptotic bodies by neutrophils induce tissue regenerative responses
Victoria Brandel, Vienna, Austria

P1.18 | Cancer associated mast cells exhibit a tumor promoting phenotype but can be effectively targeted to reinvigorate antitumor immunity in a human based ex-vivo model
Dyke Ferber, Heidelberg, Germany


Topic 2 | Emerging concepts / novel agents

P2.1 | Multispectral imaging for quantitative and compartment specific immune profiling of cancer tissue
Bjoern Wendik, Rodgau, Germany

P2.2 | Induction of tumor-specific immune responses by the TLR9 agonist EnanDIM in murine syngeneic tumor models
Barbara Volz, Berlin, Germany

P2.3 | Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on tumor cells
Eric Hatterer, Plan les ouates, Switzerland

P2.4 | 3D micro-tumors for predicting individual treatment responses to immunotherapy
Tabea Sturmheit, Hamburg, Germany

P2.5 | HDAC6 inhibitor ITF3791 enhances alloantigen presentation capabilities of myeloid cells modulating PD-L1 expression and co-stimulatory molecules
Chiara Ripamonti, Cinisello Balsamo, Italy

P2.6 | Induction of a strong and persistent antitumor immune response using liposomal vaccines in the HPV-transformed orthotopic lung tumor model TC-1
Sylvie Fournel, Illkirch, France

P2.7 | Oncolysis dominated therapeutic effect of LCMV-GP – pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model
Liesa-Marie Schreiber, Innsbruck, Austria

P2.8 | Expression of Indoleamine 2,3-dioxygenase in erlotinib-treated patients with advanced pancreatic cancer: translational results from a multi-center, randomized phase III trial.
Stephan Kruger, Munich, Germany

P2.9 | Prevention of tumor ulceration in mice – Mammary fat pad injection of tumor cells
Bettina Stahnke, Freiburg, Germany

P2.10 | Abstract withdrawn

P2.11 | Immune-related effects of the ETS factor inhibitor YK-4-279
Dina Baier, Vienna, Austria

P2.12 | Mechanism of Action of NKTR-214, a first-in-class, CD122-preferential IL-2 pathway agonist
Willem Overwijk, Houston, United States

P2.13 | The phytochemicals Curcumin and Vitamin C act as immunosensitizer
Barbara Mayer, Munich, Germany

P2.14 | An oncolytic influenza A virus expressing the mycobacterial ESAT-6 protein
Viktoria Lazlo, Vienna, Austria


Topic 3 | Checkpoint inhibition and resistance mechanisms

P3.1 | Development of an in vitro 3D model system for testing PD-1/ PDL-1 immune checkpoint inhibitors
Francesca Chiovaro, Zurich, Switzerland

P3.2 | Interlaboratory variation in PD-L1 positivity in non-small cell lung cancer patients: a nationwide study
Bregje Koomen, Utrecht, Netherlands

P3.3 | MiRNA deregulation can contribute to breakdown of MHC I class antigen processing and presenting machinery in breast cancer cells
Volodymyr Halytskiy, Kiev, Ukraine

P3.4 | Modulated electro hyperthermia as an immune modulator with checkpoint inhibitors and radiotherapy
Carrie Minnaar, Johannesburg, South Africa

P3.5 | Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma
Emma de Ruiter, Utrecht, Netherlands

P3.6 | Study of IDO1 gene expression in histological variants of colorectal carcinoma
María Turpín Sevilla, Pozuelo de Alarcón, Spain


Topic 4 | Combination therapy

P4.1 | Phase I trial of combination dendritic vaccine and immune checkpoint blockade for prevention of postoperative glioblastoma recurrence
Ling Chen, Beijing, China

P4.2 | Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis.
Sarah Sasson, Oxford, United Kingdom

P4.3 | Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
Ralf Kleef, Vienna, Austria

P4.4 | Abstract withdrawn

P4.5 | Abstract Withdrawn

P4.6 | PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer
Mohanad Nada, Sulymanyaha, Iraq

P4.7 | Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
Diana Groza, Vienna, Austria


Topic 5 | Cell therapy

P5.1 | Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in ‘DC-culture-media’ shifts the (serum) chemokine-release profile to a more ‘inflammatory’ (in culture) going along with improved antileukemic T-cell-reactivity
Marion Merle, Munich, Germany

P5.2 | Arming T cells with C-X-C-motive receptor 6 enhances infiltration of pancreatic cancer patient-derived organoids
Justyna Ogonek, Munich, Germany

P5.3 | A novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors
Clara Karches, München, Germany

P5.4 | Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of pancreatic cancer
Stefanie Lesch, Munich, Germany

P5.5 | Tumor-specific immune responses after short-term BRAF-inhibitor induction in patients with melanoma resistant to checkpoint inhibitors
Aishwarya Gokuldass, Herlev, Denmark

P5.6 | Anti-hPSMA CAR engineered NK-92 cells: An Off-The-Shelf cellular therapeutic for targeted elimination of prostate cancer cells
Gaia Zuccolotto, padova, Italy


Topic 6 | Monitoring of immunotherapy

P6.1 | Differential analysis of complex immune biology in MSI and MSS colorectal tumor microenvironments using high-plex spatial resolution
Douglas Hinerfeld, Seattle, United States

P6.2 | EGF-based vaccine: recent immunological results in advanced lung cancer and non-invasive bladder cancer patients
Zaima Mazorra, Havana, Cuba

P6.3 | Modulation of AML-blasts with clinically approved response modifiers to leukemia-derived dendritic cells(DCleu) ex vivo: DC-, T-cell- and cytokine profiles are predictive for antileukemic T-cell reactivity
Helga Schmetzer, Munich, Germany

P6.4 | Human lung cancer explants model: set up of a predictive model for treatment
Benedicte Lenoir, Heidelberg, Germany

P6.5 | Increased detection of (leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers
Michael Atzler, Munich, Germany

P6.6 | Clinical relevance of in vitro generated dendritic cells of leukemic origin to predict response to immunotherapy in patients with AML and MDS
Markus Freudenreich, Munich, Germany

P6.7 | T cell repertoire convergence and clonal expansion in cytomegalovirus infection : implications for the biomarker use of TCR-seq
Timothy Looney, Austin, United States

P6.08 | Monitoring the effect of immunomodulatory treatment on the immune repertoire using the IGX platform
N. Bonzanni, ‘s-Hertogenbosch, The Netherlands


Topic 7 | Young Researcher Session

P7.1 | morphological consequences for noncapsular lymphoid tissue in the case of malignancy of GERD
Bakhtiyar Azhken, Astana, Kazakhstan

P7.2 | Interleukin-37b exerts antitumor activity on gallbladder cancer cell line
Nichapa Lerthirunvibul, Pathumthani, Thailand

P7.3 | Tumour-infiltrating lymphocytes influence prognosis in Human Papillomavirus-positive cervical and oropharyngeal cancer: A systematic review
Christian Anderson, Liverpool, United Kingdom

P7.4 | Effects of the tumor microenvironment generated by glioblastoma multiforme cells over monocyte-derived dendritic cells
Nadia Emely Chauca Torres, Sao Paulo, Brazil

P7.5 | Innovative antitumoral platinum (II) compounds as chemotherapeutic and immunotherapeutic agents
May Wantz, Illkirch Cédex, France

P7.6 | Breast cancer patients have multifunctional tumor-reactive CD4 T cells in both blood and tumor
Mariana Pinho, São Paulo, Brazil

P7.7 | Stress granule Y-box-binding protein 1 predicts prognosis in colorectal liver metastases independent and superior to DNA damage
Andreas Winter, Vienna, Austria

P7.8 | Irradiated cancer exosomes promote M1-like polarization of macrophages and enhance their anti-tumoral responses
Victoria Stary, Vienna, Austria

P7.9 | Parasites and immunotherapy: immunostimulatory effect of Leishmania spp. in cancer treatment
Mumin Alper Erdogan, Izmir, Turkey

P7.10 | Overshooting Neutrophil Attraction by Osteopontin Inhibits Liver Regeneration after Partial Hepatectomy
David Pereyra, Vienna, Austria

P7.11 | Role of B lymphocytes in two types of precancerous liver diseases (PLD)
Nataliia Petriv, Hannover, Germany